tetano
Editor, Senior Moderator
Emerg Microbes Infect
. 2020 May 20;1-10.
doi: 10.1080/22221751.2020.1772676. Online ahead of print.
Gemcitabine, Lycorine and Oxysophoridine Inhibit Novel Coronavirus (SARS-CoV-2) in Cell Culture
Ya-Nan Zhang[SUP] 1 2 [/SUP], Qiu-Yan Zhang[SUP] 3 4 [/SUP], Xiao-Dan Li[SUP] 1 5 [/SUP], Jin Xiong[SUP] 1 [/SUP], Shu-Qi Xiao[SUP] 1 [/SUP], Zhen Wang[SUP] 6 [/SUP], Zhe-Rui Zhang[SUP] 1 2 [/SUP], Cheng-Lin Deng[SUP] 1 [/SUP], Xing-Lou Yang[SUP] 1 [/SUP], Hong-Ping Wei[SUP] 1 [/SUP], Zhi-Ming Yuan[SUP] 1 [/SUP], Han-Qing Ye[SUP] 1 [/SUP], Bo Zhang[SUP] 1 3 4 6 [/SUP]
Affiliations
Abstract
The emerging SARS-CoV-2 infection associated with the outbreak of viral pneumonia in China is ongoing worldwide. There are no approved antiviral therapies to treat this viral disease. Here we examined the antiviral abilities of three broad-spectrum antiviral compounds gemcitabine, lycorine and oxysophoridine against SARS-CoV-2 in cell culture. We found that all three tested compounds inhibited viral replication in Vero-E6 cells at noncytotoxic concentrations. The antiviral effect of gemcitabine was suppressed efficiently by the cytidine nucleosides. Additionally, combination of gemcitabine with oxysophoridine had an additive antiviral effect against SARS-CoV-2. Our results demonstrate that broad-spectrum antiviral compounds may have a priority for the screening of antiviral compounds against newly emerging viruses to control viral infection.
. 2020 May 20;1-10.
doi: 10.1080/22221751.2020.1772676. Online ahead of print.
Gemcitabine, Lycorine and Oxysophoridine Inhibit Novel Coronavirus (SARS-CoV-2) in Cell Culture
Ya-Nan Zhang[SUP] 1 2 [/SUP], Qiu-Yan Zhang[SUP] 3 4 [/SUP], Xiao-Dan Li[SUP] 1 5 [/SUP], Jin Xiong[SUP] 1 [/SUP], Shu-Qi Xiao[SUP] 1 [/SUP], Zhen Wang[SUP] 6 [/SUP], Zhe-Rui Zhang[SUP] 1 2 [/SUP], Cheng-Lin Deng[SUP] 1 [/SUP], Xing-Lou Yang[SUP] 1 [/SUP], Hong-Ping Wei[SUP] 1 [/SUP], Zhi-Ming Yuan[SUP] 1 [/SUP], Han-Qing Ye[SUP] 1 [/SUP], Bo Zhang[SUP] 1 3 4 6 [/SUP]
Affiliations
- PMID: 32432977
- DOI: 10.1080/22221751.2020.1772676
Abstract
The emerging SARS-CoV-2 infection associated with the outbreak of viral pneumonia in China is ongoing worldwide. There are no approved antiviral therapies to treat this viral disease. Here we examined the antiviral abilities of three broad-spectrum antiviral compounds gemcitabine, lycorine and oxysophoridine against SARS-CoV-2 in cell culture. We found that all three tested compounds inhibited viral replication in Vero-E6 cells at noncytotoxic concentrations. The antiviral effect of gemcitabine was suppressed efficiently by the cytidine nucleosides. Additionally, combination of gemcitabine with oxysophoridine had an additive antiviral effect against SARS-CoV-2. Our results demonstrate that broad-spectrum antiviral compounds may have a priority for the screening of antiviral compounds against newly emerging viruses to control viral infection.